Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02356965 · ClinicalTrials.gov registry record · Phase 2
Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction
A Phase 2 study, sponsored by iX Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT02356965: Completed Phase 2 study, sponsored by iX Biopharma.
NCT02356965 is a Phase 2 study that has completed, run by iX Biopharma. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02356965, a Phase 2 study, has completed, sponsored by iX Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of the study is to test two different doses of ketamine sub-lingual (under the tongue) wafer against placebo to see how effective the medication is to treat moderate to severe pain after wisdom tooth extraction.
Primary Outcome
Demonstrate the dose-response relationship for analgesia of two dose levels of ketamine sublingual wafer compared with placebo, using the summed pain intensity difference from baseline over the first 3 hours (SPID3) in subjects with acute moderate to severe pain following third molar extraction.
Interventions
- DRUG Ketamine
- DRUG Placebo (for Ketamine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
What the finished NCT02356965 record still lists
NCT02356965 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT02356965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02356965 about?
NCT02356965 is a clinical study titled "Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction". The purpose of the study is to test two different doses of ketamine sub-lingual (under the tongue) wafer against placebo to see how effective the medication is to treat moderate to severe pain after wisdom tooth extraction.
What is the current status of trial NCT02356965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2014-12. Estimated completion is 2015-02.
What interventions are being tested in trial NCT02356965?
The interventions under investigation include: Ketamine (DRUG), Placebo (for Ketamine) (DRUG).
Who is sponsoring clinical trial NCT02356965?
This trial is sponsored by iX Biopharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02356965's enrollment target sits among peer trials
80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia